Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Legochem Biosciences Inc. has 1 pending office action in Biotechnology & Pharmaceuticals. The file involves 1 distinct examiner and 1 art unit, producing a concentrated examination profile.
CANELLA, KAREN A is the identified examiner. The prosecution response should focus on the biotechnology claims at issue, with careful attention to written support and to the technical distinctions that can be defended from the existing application.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PECKHAM, RICHARD GRANT | 1 | 67.8% | +35.9% |
| CANELLA, KAREN A | 1 | 62.3% | +32.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17758241 | PYRROLOBENZODIAZEPINE DERIVATIVE AND LIGAND-LINKER CONJUGATE THEREOF | PECKHAM, RICHARD GRANT | 15d overdue |
| 17607678 | LIGAND-DRUG CONJUGATE INCLUDING LINKER HAVING TRIS STRUCTURE | CANELLA, KAREN A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17758241 | PYRROLOBENZODIAZEPINE DERIVATIVE AND LIGAND-LINKER CONJUGATE THEREOF | PECKHAM, RICHARD GRANT | 15d overdue |
| 17607678 | LIGAND-DRUG CONJUGATE INCLUDING LINKER HAVING TRIS STRUCTURE | CANELLA, KAREN A | — |
| Art Unit | Apps |
|---|---|
| 1627 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17758241 | PYRROLOBENZODIAZEPINE DERIVATIVE AND LIGAND-LINKER CONJUGATE THEREOF | PECKHAM, RICHARD GRANT | 1627 | §103§112 | Non-Final OA | 15d overdue | Pending | Dec 28, 2022 |
| 17607678 | LIGAND-DRUG CONJUGATE INCLUDING LINKER HAVING TRIS STRUCTURE | CANELLA, KAREN A | 1643 | §102§112 | Final Rejection | — | Pending | Oct 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialLegochem Biosciences Inc. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Richard Grant Peckham has the most, with 1 of Legochem Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.